Citadel Advisors’s Dynavax Technologies DVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-61,300
Closed -$943K 13237
2025
Q4
$943K Buy
61,300
+50,600
+473% +$557K ﹤0.01% 7526
2025
Q3
$106K Sell
10,700
-24,500
-70% -$255K ﹤0.01% 11809
2025
Q2
$349K Buy
35,200
+25,800
+274% +$272K ﹤0.01% 9448
2025
Q1
$122K Buy
9,400
+3,400
+57% +$45K ﹤0.01% 11184
2024
Q4
$76.6K Sell
6,000
-3,000
-33% -$36.3K ﹤0.01% 11840
2024
Q3
$100K Sell
9,000
-6,500
-42% -$71.7K ﹤0.01% 11112
2024
Q2
$174K Sell
15,500
-101,300
-87% -$1.18M ﹤0.01% 10132
2024
Q1
$1.45M Buy
116,800
+100,900
+635% +$1.32M ﹤0.01% 6155
2023
Q4
$222K Sell
15,900
-14,000
-47% -$194K ﹤0.01% 9737
2023
Q3
$442K Buy
29,900
+7,700
+35% +$108K ﹤0.01% 8331
2023
Q2
$287K Sell
22,200
-2,600
-10% -$29.6K ﹤0.01% 9148
2023
Q1
$243K Sell
24,800
-117,200
-83% -$1.25M ﹤0.01% 9818
2022
Q4
$1.51M Sell
142,000
-14,600
-9% -$170K ﹤0.01% 6019
2022
Q3
$1.64M Buy
156,600
+16,600
+12% +$216K ﹤0.01% 5979
2022
Q2
$1.76M Sell
140,000
-11,200
-7% -$119K ﹤0.01% 5806
2022
Q1
$1.64M Sell
151,200
-32,800
-18% -$398K ﹤0.01% 6533
2021
Q4
$2.59M Sell
184,000
-158,800
-46% -$2.61M ﹤0.01% 5636
2021
Q3
$6.58M Buy
342,800
+115,400
+51% +$1.53M ﹤0.01% 3786
2021
Q2
$2.24M Sell
227,400
-14,100
-6% -$128K ﹤0.01% 6312
2021
Q1
$2.37M Buy
241,500
+167,200
+225% +$1.38M ﹤0.01% 5997
2020
Q4
$331K Sell
74,300
-18,200
-20% -$82.4K ﹤0.01% 8896
2020
Q3
$400K Buy
92,500
+35,700
+63% +$255K ﹤0.01% 7665
2020
Q2
$504K Buy
56,800
+21,200
+60% +$107K ﹤0.01% 7062
2020
Q1
$126K Sell
35,600
-24,400
-41% -$113K ﹤0.01% 8442
2019
Q4
$343K Buy
60,000
+5,300
+10% +$28.3K ﹤0.01% 7381
2019
Q3
$196K Buy
54,700
+2,200
+4% +$8.53K ﹤0.01% 8164
2019
Q2
$209K Sell
52,500
-31,700
-38% -$184K ﹤0.01% 8128
2019
Q1
$616K Sell
84,200
-18,400
-18% -$180K ﹤0.01% 6423
2018
Q4
$939K Sell
102,600
-24,300
-19% -$269K ﹤0.01% 5409
2018
Q3
$1.57M Buy
126,900
+22,600
+22% +$306K ﹤0.01% 4788
2018
Q2
$1.59M Sell
104,300
-1,200
-1% -$20.7K ﹤0.01% 4449
2018
Q1
$2.09M Buy
105,500
+29,300
+38% +$506K ﹤0.01% 3670
2017
Q4
$1.43M Buy
76,200
+22,700
+42% +$456K ﹤0.01% 4106
2017
Q3
$1.15M Sell
53,500
-24,200
-31% -$383K ﹤0.01% 4123
2017
Q2
$750K Buy
77,700
+15,200
+24% +$98.7K ﹤0.01% 4533
2017
Q1
$372K Sell
62,500
-51,200
-45% -$246K ﹤0.01% 5529
2016
Q4
$449K Buy
113,700
+38,700
+52% +$283K ﹤0.01% 5070
2016
Q3
$787K Buy
75,000
+26,700
+55% +$384K ﹤0.01% 4148
2016
Q2
$704K Sell
48,300
-11,000
-19% -$188K ﹤0.01% 4023
2016
Q1
$1.14M Buy
59,300
+35,100
+145% +$709K ﹤0.01% 3328
2015
Q4
$585K Buy
24,200
+11,600
+92% +$291K ﹤0.01% 4260
2015
Q3
$309K Buy
12,600
+1,500
+14% +$42.5K ﹤0.01% 5518
2015
Q2
$260K Buy
11,100
+3,800
+52% +$82.8K ﹤0.01% 5949
2015
Q1
$164K Buy
7,300
+4,500
+161% +$86.2K ﹤0.01% 6389
2014
Q4
$47K Buy
2,800
+1,960
+233% +$29.9K ﹤0.01% 7241
2014
Q3
$12K Sell
840
-860
-51% -$12.4K ﹤0.01% 7693
2014
Q2
$27K Sell
1,700
-300
-15% -$4.52K ﹤0.01% 7136
2014
Q1
$36K Sell
2,000
-860
-30% -$15.9K ﹤0.01% 6981
2013
Q4
$56K Buy
2,860
+560
+24% +$8.2K ﹤0.01% 5974
2013
Q3
$28K Buy
2,300
+560
+32% +$7.05K ﹤0.01% 6062
2013
Q2
$19K Buy
+1,740
New +$36.7K ﹤0.01% 6081

Other funds holding DVAX

Citadel Advisors's DVAX Position: Q1 2026 in Review

Citadel Advisors sold out of Dynavax Technologies (DVAX) in Q1 2026, closing a stake of 116,684 shares — an estimated $1.79M sold.

Citadel Advisors first reported a position in DVAX in Q2 2013 and held it in 50 quarters. The position peaked at $38.5M in Q3 2023. 1 fund tracked by Wall St. Rank holds DVAX as of Q1 2026.

  • Citadel Advisors reported no remaining Dynavax Technologies position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 116,684 Dynavax Technologies shares in Q1 2026, an estimated $1.79M.
  • Citadel Advisors first reported a position in Dynavax Technologies in Q2 2013 and held it in 50 quarters.
  • Citadel Advisors's Dynavax Technologies position peaked at $38.5M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Dynavax Technologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.